Dual targeting of CDK4 and MEK as a combination treatment strategy for metastatic colorectal cancer

被引：1
|
作者：
Ziemke, Elizabeth [1 ]
Dosch, Joseph [1 ]
Shettigar, Amrith [1 ]
Wan, Shanshan [2 ]
Welling, Theodore [2 ]
Hardiman, Karin [2 ]
Sebolt-Leopold, Judith [1 ]
机构：
[1] Univ Michigan, Dept Radiol, Translat Oncol Program, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-4541
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4541
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
    Sorokin, Alexey V.
    Marie, Preeti Kanikarla
    Bitner, Lea
    Syed, Muddassir
    Woods, Melanie
    Manyam, Ganiraju
    Kwong, Lawrence N.
    Johnson, Benny
    Morris, Van K.
    Jones, Philip
    Menter, David G.
    Lee, Michael S.
    Kopetz, Scott
    CANCER RESEARCH, 2022, 82 (18) : 3335 - 3344
  • [2] Dual CDK4/ARK5 inhibition by ON 123300 for targeting metastatic colorectal cancer
    Reddy, M.
    Cosenza, Stephen
    Divakar, Saikrishna
    Akula, Balireddy
    Mallireddigari, Muralidhar
    Reddy, Premkumar
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [3] Dual CDK4/ARK5 inhibition by ON 123300 for targeting metastatic colorectal cancer
    Reddy, M.
    Cosenza, Stephen
    Divakar, Saikrishna
    Akula, Balireddy
    Mallireddigari, Muralidhar
    Reddy, Premkumar
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [4] Dual targeting of CDK4/6 and MET in metastatic uveal melanoma
    Ohara, Masahiro
    Saito, Kengo
    Kageyama, Ken
    Terai, Mizue
    Cheng, Hanyin
    Aplin, Andrew E.
    Sato, Takami
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
    Ohara, Masahiro
    Saito, Kengo
    Kageyama, Ken
    Terai, Mizue
    Cheng, Hanyin
    Aplin, Andrew E.
    Sato, Takami
    CANCERS, 2021, 13 (05) : 1 - 19
  • [6] Dual targeting of ARK5 and CDK4 pathways with ON 123300 as a therapeutic strategy for colorectal carcinoma
    Divakar, Saikrishna A.
    Reddy, M. V. Ramana
    Cosenza, Stephen C.
    Baker, Stacey J.
    Purohit, Vinee
    Gunda, Venugopal
    Singh, Pankaj K.
    Reddy, E. Premkumar
    CANCER RESEARCH, 2016, 76
  • [7] Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
    Lee, Michael S.
    Helms, Timothy L.
    Feng, Ningping
    Gay, Jason
    Chang, Qing Edward
    Tian, Feng
    Wu, Ji Y.
    Toniatti, Carlo
    Heffernan, Timothy P.
    Powis, Garth
    Kwong, Lawrence N.
    Kopetz, Scott
    ONCOTARGET, 2016, 7 (26) : 39595 - 39608
  • [8] Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer
    Pek, M.
    Yatim, S. M. J. M.
    Chen, Y.
    Li, J.
    Gong, M.
    Jiang, X.
    Zhang, F.
    Zheng, J.
    Wu, X.
    Yu, Q.
    ONCOGENE, 2017, 36 (35) : 4975 - 4986
  • [9] Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer
    M Pek
    S M J M Yatim
    Y Chen
    J Li
    M Gong
    X Jiang
    F Zhang
    J Zheng
    X Wu
    Q Yu
    Oncogene, 2017, 36 : 4975 - 4986
  • [10] Targeting CDK4 and CDK6 in cancer
    Shom Goel
    Johann S. Bergholz
    Jean J. Zhao
    Nature Reviews Cancer, 2022, 22 : 356 - 372
12345